Bartlomiej Kalaska

Dr. Bartlomiej Kalaska

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
ESEmilia Sokołowska
Emilia Sokołowska
BKBartlomiej Kalaska
Bartlomiej Kalaska
JMJoanna Miklosz
Joanna Miklosz
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
Introduction: Unfractionated heparin is a strongly anionic anticoagulant used extensively in medicine to prevent blood clotting. In the case of an emergency bleeding in response to heparin, the protamine sulfate is administered. Despite its extensive clinical use, protamine may produce life-threatening side effects such as systemic hypotension, catastrophic pulmonary vasoconstriction or allergic reactions. Recent studies have demonstrated new organ-specific complications of the heparin reversal with protamine. Areas covered: Past and present knowledge of the mechanisms responsible for the toxicity of protamine and the most promising potential replacements of protamine in the different phases of development. Expert opinion: Despite of the low therapeutic index, protamine is the only registered antidote of heparins. The toxicology of protamine depends on a complex interaction of the high molecular weight, a cationic peptide with the surfaces of the vasculature and blood cells. The mechanisms involve membrane receptors and ion channels targeted by different vasoactive compounds, such as nitric oxide, bradykinin or histamine. Unacceptable side effects of protamine have led to a search for new alternatives: UHRA, LMWP, and Dex40-GTMAC3 are in the preclinical stage; the two other agents (andexanet alfa and PER977) are already in the advanced clinical phases.

11 June 2020 in Scientific Reports
Verified
Journal Article
Open access
MKMałgorzata Karbowska
Małgorzata Karbowska
JHJustyna M. Hermanowicz
Justyna M. Hermanowicz
ATAnna Tankiewicz-Kwedlo
Anna Tankiewicz-Kwedlo
BKBartlomiej Kalaska
Bartlomiej Kalaska
TKTomasz W. Kaminski
Tomasz W. Kaminski
DPDariusz Pawlak
Dariusz Pawlak
Chronic kidney disease (CKD) is deemed to be a worldwide health concern connected with neurological manifestations. The etiology of central nervous system (CNS) disorders in CKD is still not fully understood, however particular attention is currently being paid to the impact of accumulated toxins. Indoxyl sulfate (IS) is one of the most potent uremic toxins. The purpose of the present study was to assess IS concentrations in the cerebellum, brainstem, cortex, hypothalamus, and striatum with hippocampus of rats chronically exposed to IS. To evaluate IS impact on neurochemical and behavioral alterations, we examined its influence on brain levels of norepinephrine, epinephrine, dopamine, serotonin and their metabolites, as well as changes in behavioral tests (open field test, elevated plus maze test, chimney test, T maze test, and splash test). Our results show the highest IS accumulation in the brainstem. IS leads to behavioral alterations involving apathetic behavior, increased stress sensitivity, and reduced locomotor and exploratory activity. Besides, IS contributes to the impairment of spatial memory and motor coordination. Furthermore, we observed reduced levels of norepinephrine, dopamine or serotonin, mainly in the brainstem. Our findings indicate that IS can be one of the crucial uremic factors responsible for altered mental status in CKD.

13 March 2014 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
BKBartlomiej Kalaska
Bartlomiej Kalaska
LPLukasz Piotrowski
Lukasz Piotrowski
ALAgnieszka Leszczynska
Agnieszka Leszczynska
Bartosz MichalowskiBartosz Michalowski
Bartosz Michalowski
KKKarol Kramkowski
Karol Kramkowski
WBWlodzimierz Buczko
Wlodzimierz Buczko

31 October 2017 in Frontiers in Physiology
Verified
Journal Article
Open access
BKBartlomiej Kalaska
Bartlomiej Kalaska
KPKrystyna Pawlak
Krystyna Pawlak
TDTomasz Domaniewski
Tomasz Domaniewski
EOEwa Oksztulska-Kolanek
Ewa Oksztulska-Kolanek
BZBeata Znorko
Beata Znorko
Dariusz PawlakDariusz Pawlak
Dariusz Pawlak
The diagnosis and treatment of bone disorders in patients with chronic kidney disease (CKD) represent a clinical challenge. CKD leads to mineral and bone complications starting early in the course of renal failure. Recently, we have observed the positive relationship between intensified central kynurenine turnover and bone strength in rats with subtotal 5/6 nephrectomy (5/6 Nx)-induced CKD. The aim of the present study was to determine the association between peripheral kynurenine pathway metabolites and bone strength in rats with 5/6 Nx-induced CKD. The animals were sacrificed one and three months after 5/6 Nx or sham operation. Nephrectomized rats presented higher concentrations of serum creatinine, urea nitrogen, and parathyroid hormone both one and three months after nephrectomy. These animals revealed higher concentrations of kynurenine and 3-hydroxykynurenine in the serum and higher gene expression of aryl hydrocarbon receptor (AhR) as a physiological receptor for kynurenine and AhR-dependent cytochrome in the bone tissue. Furthermore, nephrectomy significantly increased the number of osteoclasts in the bone without affecting their resorptive activity measured in serum. These changes were particularly evident in rats one month after 5/6 Nx. The main bone biomechanical parameters of the tibia were unchanged between nephrectomized and sham-operated rats but were significantly increased in older compared to younger animals. A similar trend was observed for geometrical parameters measured with calipers, bone mineral density based on Archimedes' method and image of bone microarchitecture obtained from micro-computed tomography analyses of tibial cortical bone. In nephrectomized animals, peripheral kynurenine levels correlated negatively with the main parameters of bone biomechanics, bone geometry, and bone mineral density values. In conclusion, our data suggest that CKD-induced elevated levels of peripheral kynurenine cause pathological changes in bone structure via AhR pathway. This finding opens new opportunities for the treatment/prevention of osteoporosis in CKD.

1 July 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BKBartlomiej Kalaska
Bartlomiej Kalaska
ESEmilia Sokołowska
Emilia Sokołowska
KKKamil Kaminski
Kamil Kaminski
KSKrzysztof Szczubialka
Krzysztof Szczubialka
KKKarol Kramkowski
Karol Kramkowski
WBWlodzimierz Buczko
Wlodzimierz Buczko

17 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BKBartlomiej Kalaska
Bartlomiej Kalaska
KKKamil Kaminski
Kamil Kaminski
ESEmilia Sokołowska
Emilia Sokołowska
DCDominik Czaplicki
Dominik Czaplicki
MKMonika Kujdowicz
Monika Kujdowicz
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a number of adverse effects, such as anaphylactic shock or serious hypotension. We aimed to develop an alternative UFH antidote as efficient as protamine, but safer and easier to produce. As a starting material, we have chosen generally non-toxic, biocompatible, widely available, inexpensive, and easy to functionalize polysaccharides. Our approach was to synthesize, purify and characterize cationic derivatives of dextran, hydroxypropylcellulose, pullulan and γ-cyclodextrin, then to screen them for potential heparin-reversal activity using an in vitro assay and finally examine efficacy and safety of the most active polymers in Wistar rat and BALB/c mouse models of experimentally induced arterial and venous thrombosis. Efficacy studies included the measurement of thrombus formation, activated partial thromboplastin time, bleeding time, and anti-factor Xa activity; safety studies included the measurement of hemodynamic, hematologic and immunologic parameters. Linear, high molecular weight dextran substituted with glycidyltrimethylammonium chloride groups at a ratio of 0.65 per glucose unit (Dex40-GTMAC3) is the most potent and the safest UFH inhibitor showing activity comparable to that of protamine while possessing lower immunogenicity. Cationic polysaccharides of various structures neutralize UFH. Dex40-GTMAC3 is a promising and potentially better UFH antidote than protamine.